BURLINGTON, Mass., Oct. 16, 2015 (GLOBE NEWSWIRE) — LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that China’s Food and Drug Administration has approved the registration of the Company’s TRIVEX System. The registration triggers a previously signed five-year, $7.8 million distribution agreement with LeMaitre Vascular’s exclusive TRIVEX distributor in China.
“We are pleased to receive this approval in the timeframe we expected,” said George W. LeMaitre, Chairman and CEO. “It demonstrates progress on our China strategy.”
TRIVEX is a Transilluminated Powered Phlebectomy System, offering a minimally invasive way to remove varicose veins in a matter of minutes.
About LeMaitre Vascular
LeMaitre Vascular is a provider of devices and implants for the treatment of peripheral vascular disease, a condition that affects more than 20 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. The Company’s diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. Additional information can be found at www.lemaitre.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding the Company’s business that are not historical facts may be “forward-looking statements” that involve risks and uncertainties. Forward-looking statements are based on management’s current, preliminary expectations and are subject to risks and uncertainties that could cause actual results to differ from the results predicted. These risks and uncertainties include, but are not limited to, the risk that the Company may not achieve success with the TRIVEX system in China and other risks and uncertainties included under the heading “Risk Factors” in its most recent Annual Report on Form 10-K, as updated by its subsequent filings with the SEC, all of which are available on the Company’s investor relations website at www.lemaitre.com and on the SEC’s website at www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
CONTACT: Contact: LeMaitre Vascular, Inc. Beth Kurth +1-781-425-1659 firstname.lastname@example.org